AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Changes in drug interaction profiles for first-line HIV therapy over the 20 years of the Liverpool Drug Interaction website.View Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019The initial Phase 1 evaluation of the safety, tolerability, and pharmacokinetics of GSK3640254, a next generation HIV maturation inhibitor, as assessed in healthy subjectsView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Population pharmacokinetics of VRC01 in infants and adultsView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019In silico design of a microarray patch as a multipurpose prevention technologyView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Efavirenz pharmacokinetics in HIV/TB coinfected persons initiating ART while receiving high dose rifapentineView Abstract
SlidesetRSVHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Sexual health clinic-based delivery model - Rena Janamnuaysook, MBAView Slideset
SlidesetViral Hepatitis and Liver DiseaseRSVHIVInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Pharmacokinetics of tenofovir alafenamide 25 mg with PK boosters during pregnancy and postpartum - Kristina Brooks, PharmDView Slideset
SlidesetViral Hepatitis and Liver DiseaseRSVHIVInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019CRISPR/Cas and gene editing for HIV - Paula Cannon, PhDView Slideset
SlidesetViral Hepatitis and Liver DiseaseRSVHIVInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Utilization of physiologically based pharmacokinetic modelling (PBPK) to predict the effect of UGT enzyme inhibition and induction on the systemic exposure of Cabotegravir - Aarti PatelView Slideset
SlidesetViral Hepatitis and Liver DiseaseRSVHIVInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Physiologically-based pharmacokinetic modeling of rilpivirine during pregnancy - Mary GockenbachView Slideset
SlidesetViral Hepatitis and Liver DiseaseRSVHIVInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Physiologically based pharmacokinetic modelling to determine pharmacokinetic alterations driving ritonavir exposure changes in aging people living with HIV - Felix StaderView Slideset
SlidesetViral Hepatitis and Liver DiseaseRSVHIVInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019An exploration of adherence measures to detect recent changes in Truvada® dosing patterns - Daijha AndersonView Slideset
